MeMed is transforming patient care by listening to the immune system and turning host response signals into clinical action.
We developed a pioneering test to help physicians with the seemingly simple clinical dilemma - is it a bacterial or viral infection?
By providing host response information, we help physicians make more informed decisions about how and when to treat. From a small serum sample, MeMed BV computationally integrates the level of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response or co-infection versus a likely virtual immune response.
The Host Immune Response Can Overcome Limitations of Current Diagnostic Challenges
Inaccessible infection sites
Often no pathogens are detected
False alarms due to colonization
Prolonged time to results
Uncertainty regarding severity
A cutting-edge technology, compact, multi-purpose platform quantitative diagnostic immunoassays that open the way to central lab performance at the point of need, using chemiluminescence detection technology.
MeMed Key runs the MeMed BV™ test within 15 minutes.
*MeMed BV® test and the MeMed Key® platform, have both been granted 510(k) clearance by the U.S. @FDA
At MeMed, a leader in host response technologies, we decode the body's complex signals into simple insights that improve people's lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas.